Sanofi (SNY)
(Delayed Data from NSDQ)
$51.73 USD
+0.47 (0.92%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.73 USD
+0.47 (0.92%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
What's in the Offing for Regeneron (REGN) in Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3.
Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark
by Zacks Equity Research
Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
by Zacks Equity Research
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Top Analyst Reports for AbbVie, Berkshire & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Berkshire Hathaway (BRK.B) and PepsiCo (PEP).
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
by Zacks Equity Research
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
by Zacks Equity Research
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU
by Zacks Equity Research
Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.
EMA Accepts Regeneron/Sanofi's application for Dupixent
by Zacks Equity Research
Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
by Zacks Equity Research
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Amgen's Repatha Gains CHMP Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Immune Design Poised on Progress of Pipeline Candidates
by Zacks Equity Research
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Is Sanofi (SNY) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Top Research Report for AT&T, Goldman Sachs & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Goldman Sachs (GS) and Sanofi (SNY).
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
by Zacks Equity Research
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Regeneron and Sanofi Announce Positive Data on Praluent
by Zacks Equity Research
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.